Related Experiment Videos
Predictive factors for late toxicity after endobronchial brachytherapy: a multivariate analysis
C Hennequin1, J Tredaniel, S Chevret
1Service de Cancérologie-Radiothérapie, Höpital Saint-Louis, Paris, France.
International Journal of Radiation Oncology, Biology, Physics
|September 25, 1998
Summary
Endobronchial brachytherapy can cause hemoptysis, often linked to disease progression and tumor length. Radiation bronchitis is associated with tumor location and treatment technical factors, suggesting areas for improving this lung cancer therapy.
Area of Science:
- Oncology
- Radiation Oncology
- Pulmonology
Background:
- Endobronchial brachytherapy is a treatment for lung tumors.
- Understanding complications like hemoptysis and radiation bronchitis is crucial for patient safety and treatment optimization.
Purpose of the Study:
- To identify predictive factors for hemoptysis and radiation bronchitis following endobronchial brachytherapy.
- To differentiate clinical and technical factors influencing these adverse events using univariate and multivariate analyses.
Main Methods:
- 149 patients undergoing endobronchial brachytherapy were analyzed.
- Patients were categorized into palliative, curative, or combined external irradiation groups.
- Variables including patient demographics, tumor characteristics, and radiation dosimetry were assessed.
Main Results:
- Hemoptysis (7.4%) was primarily associated with disease progression and endobronchial tumor length.
- Radiation bronchitis (8.7%) was linked to tumor location (trachea, main stem bronchus) and technical factors (total dose, 100% isodose volume).
Conclusions:
- Hemoptysis is mainly driven by disease progression, potentially exacerbated by brachytherapy.
- Radiation bronchitis is influenced by tumor location and treatment parameters, indicating potential for technical refinement.
- Optimizing brachytherapy techniques may improve the therapeutic ratio for lung cancer patients.